Cepheid

Cepheid is a leading player in the field of molecular diagnostics, established in 1996 and headquartered in the United States. The company's innovative GeneXpert® systems and Xpert® tests revolutionize PCR testing by automating complex procedures that traditionally required significant time and expertise.

Cepheid offers a comprehensive test portfolio that addresses a range of critical healthcare needs, including respiratory infections, blood virology, women's and sexual health, TB, and emerging infectious diseases. Their solutions are designed to deliver rapid, actionable results across diverse settings, enhancing decision-making processes in both central laboratories and near-patient scenarios.

Backed by the robust support of Danaher, a leader in science and technology, Cepheid benefits from an expansive network of expertise and resources, maximizing its impact in the Biotechnology and Health Care industries. The last reported funding for Cepheid was a grant investment in October 2021.